论文部分内容阅读
目的探讨厄洛替尼治疗晚期非小细胞肺癌的临床效果。方法回顾性分析2014年1月—2015年12月在信阳市肿瘤医院住院时采取厄洛替尼治疗的56例晚期非小细胞肺癌患者临床病例资料,总结厄洛替尼临床治疗效果和不良反应。结果 56例晚期非细胞癌患者经厄洛替尼治疗后,疾病完全缓解者2例,占3.6%,部分缓解者14例,占25.0%,疾病稳定者23例,占41.1%,疾病进展者17例,占30.4%;患者在服用厄洛替尼后其不良反应主要为腹泻、恶心、呕吐、皮疹等,不良反应发生程度均较轻微,采取积极对症处理后不良反应均消失。结论采用厄洛替尼治疗晚期非小细胞肺癌患者具有较好的临床效果,且未见严重不良反应发生。
Objective To investigate the clinical effect of erlotinib in the treatment of advanced non-small cell lung cancer. Methods Clinical data of 56 patients with advanced non-small cell lung cancer treated with erlotinib in hospital from January 2014 to December 2015 in hospital from January 2014 to December 2015 were analyzed retrospectively to summarize the clinical efficacy and adverse reactions of erlotinib . Results 56 cases of advanced non-cell carcinoma patients after erlotinib treatment, complete remission in 2 cases, accounting for 3.6%, partial remission in 14 cases, accounting for 25.0%, stable disease in 23 cases (41.1%), disease progression 17 cases, accounting for 30.4%; patients taking erlotinib after adverse reactions were mainly diarrhea, nausea, vomiting, rash, adverse reactions were mild, adverse reactions were disappeared after positive symptomatic treatment. Conclusion The erlotinib treatment of advanced non-small cell lung cancer patients have a good clinical effect, and no serious adverse reactions.